top of page
News & Updates
I'm a paragraph. Click here to add your own text and edit me. It’s easy. Just click “Edit Text” or double click me to add your own content and make changes to the font.
An EGFR Targeted PET Imaging Probe for the Detection of Colonic Adenocarcinomas
Theranostics. 2014; 4(9): 893–903. Colorectal cancer is a serious complication associated with inflammatory bowel disease, often...
Jun 18, 2021
PET imaging of glioblastoma multiforme EGFR expression for therapeutic decision guidance
Am J Nucl Med Mol Imaging. 2015; 5(4): 379–389. After initial therapy and total resection of glioblastoma multiforme (GBM), 80-90% of...
Jun 18, 2021
18 F-FES PET/CT Measurement of ER Suppression during a Phase I Trial of GDC-0810
Clin Cancer Res; 23(12); 3053-60. Purpose: Evaluate 18F-fluoroestradiol (FES) PET/CT as a biomarker of estrogen receptor (ER) occupancy...
Jun 18, 2021
A phase one, single-dose, open-label, clinical safety and PET/MR imaging study of 68 Ga-DOTATOC
Am J Nucl Med Mol Imaging. 2017; 7(2): 53–62. This prospective pilot study provides a dynamic whole body PET/MR image database, clinical...
Jun 15, 2021
Synthesis and preliminary PET imaging of of the ROS1/ALK inhibitor lorlatinib
Nat Commun. 2017 Jun 8;8:15761. Lorlatinib (PF-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine...
Jun 15, 2021
Specific 18F-FDHT Accumulation in Human Prostate Cancer Models Is Facilitated by Prebinding to SHBG
J Nuclear Med. 2018 Apr;20(2):300-308. Purpose: Tremendous efforts are currently dedicated to the development of novel therapies...
Jun 15, 2021
Phage Display Selection, In Vitro Characterization, and Correlative PET Imaging of a HER3 Peptide
Mol Imaging Biol. 2018 Apr;20(2):300-308. HER3 (ERBB3) is a receptor tyrosine kinase that is implicated in treatment resistance across...
Jun 15, 2021
Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance
J Nucl Med. 2016 Sep;57(9):1413-9. Purpose: Inhibitors of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of...
Jun 15, 2021
HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib
Mol Imaging Biol. 2021 Jun 8. Purpose: Standard therapy for HER2+ breast cancers includes HER2 inhibition. While HER2 inhibitors have...
Jun 15, 2021
HER3 Differentiates Basal From Claudin Type TNBC and Contributes to Drug Resistance
Front Oncol. 2020 Nov 20;10:554704. Triple Negative Breast Cancer (TNBC) is an aggressive form of Breast Cancer (BC). Numerous kinase...
Jun 15, 2021
Optical Imaging of MET for Enhanced Detection and Characterization of Hepatic Tumors
Theranostics. 2016 Sep 9;6(12):2028-2038. Purpose: To assess optical imaging of Mesenchymal-Epithelial Transition factor (MET) for...
Jun 14, 2021
Somatostatin receptor type 2 as a radiotheranostic PET reporter gene for oncologic interventions
Theranostics. 2018 May 23;8(12):3380-3391. Purpose: Reporter gene systems can serve as therapy targets. However, the therapeutic use of...
Jun 13, 2021
Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader
Clin Cancer Res. 2015 Mar 15;21(6):1340-7. Purpose: Estrogen receptor (ER) targeting is key in management of receptor-positive breast...
Jun 13, 2021
Free SSTR fraction predicts the antiproliferative effect of octreotide in NETs
Cancer Res. 2013 Dec 1;73(23):6865-73. Somatostatin receptors (SSTR) are highly expressed in well-differentiated neuroendocrine tumors...
Jun 13, 2021
bottom of page